Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T05:08:48.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Valuing Intellectual Property Rights in an Imperfectly Competitive Market: A Biopharming Application

Published online by Cambridge University Press:  26 January 2015

Genti Kostandini  and
Bradford F. Mills
Genti Kostandini
Affiliation:
Department of Agricultural and Applied Economics, University of Georgia, Griffin, GA
Bradford F. Mills
Affiliation:
Department of Agricultural and Applied Economics, Virginia Polytechnic Institute and State University, Blacksburg, VA
Get access Rights & Permissions [Opens in a new window]

Abstract

Small research firms developing biotechnology applications often focus on establishing intellectual property rights (IPRs), which can then be sold to more established firms with existing market channels. This paper presents a method for valuing the IPRs for an innovation that lowers product production costs below those associated with the patented process of a monopolist. The application to Glucocerebrosidase enzyme from transgenic tobacco suggests an IPRs value of about $1.75 billion. Despite the innovator's market power, significant surplus gains also accrue to consumers. Further, U.S. antitrust laws that prohibit IPRs acquisition by the current monopolist increase consumer welfare by almost 50%.

Keywords

biopharmaceuticalsbiopharmingeconomic surplusimperfect competitionintellectual property rightsD23M13D43D60
Type
Research Article
Information
Journal of Agricultural and Applied Economics , Volume 41 , Issue 3 , December 2009 , pp. 571 - 583
Copyright
Copyright © Southern Agricultural Economics Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allen, B. “Price and Quantity Competition in Homogeneous Markets.” Economics Letters 38(1992):417–22.CrossRefGoogle Scholar
Alpert, B. “Ripe for the Picking: Little Biotech Firms are Catching the Eye of Big Pharma Juicy Stocks.” Baron's Online April 19, 2004. Internet site: http://www.somaxon.com/media/pdf/press2004/Barrons_RipeForPicking_Article.pdf (Accessed May 25, 2005).Google Scholar
Alston, J.M., Norton, G.W., and Pardey., P.G. Science Under Scarcity: Principles and Practice for Agricultural Research Evaluation and Priority Setting. New York: Cornell University Press, 1996.Google Scholar
Balto, D.A., and Mongoven., J.F. “Antitrust Enforcement in Pharmaceutical Industry Mergers.” Food and Drug Law Journal 54,3(1999):255–78.Google Scholar
Begemann, B.D. “Competitive Strategies of Biotechnology Firms: Implications for U.S. Agriculture.” Journal of Agricultural and Applied Economics 29(1997): 117–22.Google Scholar
Cramer, C.L., Weissenborn, D.L., Oishi, K.K., Grabau, E.A., Bennett, S., Ponce, E., Grabowski, G.A., and Radin., D.A. “Bioproduction of Human Enzymes in Transgenic Tobacco.” Annals of the New York Academy of Sciences 792(1996):62–72.Google Scholar
CNN. From Orphan to Blockbuster? July 2005. Internet site: http://money.cnn.com/2005/07/ 08/news/midcaps/orphan/index.htm (Accessed June 1, 2008).Google Scholar
Evangelista, R.L., Kusnadi, A.R., Howard, J.A., and Nikolov., Z.L. “Process and Economic Evaluation of the Extraction and Purification of Recombinant ß-glucuronidase from Transgenic Corn.” Biotechnology Progress 14(1998):607–14.Google Scholar
Farid, S.S. “Process Economics of Industrial Monoclonal Antibody Manufacture.” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 848(2007):8—18.Google Scholar
Font, J.C., and Kanavos., P. “Generic Competition in the Drug Markets and the Impact of Regulation.” Conference of the International Health Association, Copenhagen, July 8-11, 2007.Google Scholar
Food and Drug Administration (FDA). Generic Competition and Drug Prices. 2006. Internet site: http://www.fda.gov/cder/ogd/generic_competition.htm (Accessed August 15, 2008).Google Scholar
Genzyme Corporation. Annual Report. 2005. Internet site: http://www.genzyme.com/corp/investors/fin_fact.asp (Accessed April 15, 2005).Google Scholar
Gillis, J. Ernst & Young Release Global Biotech Report at BIO. 2002. Internet site: http://www.pharmahorizons.com/ErnstYoung.asp (Accessed May 3, 2005).Google Scholar
Glacken, M.W. “Plant Transgenics vs. Animal Transgenics vs. CHO Bioreactor Culture: An Objective Comparison for Monoclonal Antibody Production.” IBC's 8th Conference on Antibody Production and Downstream Processing, San Diego, February 8-12, 2002.Google Scholar
Goozner, M. “The Price Isn't Right.” The American Prospect (November 30, 2002). Internet site: http://www.prospect.org/cs/articles7article=the_price_isn_right (Accessed March 17, 2005).Google Scholar
Grabowski, H., and Vernon., H. “Innovation and Structural Change in Pharmaceuticals and Biotechnology.” Industrial and Corporate Change 3(1994):435-49.Google Scholar
Hamilton, J., and Slutsky., S. “Endogenous Timing in Duopoly Games: Stackelberg or Cournot Equilibria.” Games and Economic Behavior 2(1990):29–46.Google Scholar
Harsanyi, J., and Selten., R. A General Theory of Equilibrium Selection in Games. Massachusetts: MIT Press, 1998.Google Scholar
Kreps, D., and Scheinkman., J. “Quantity Pre-commitment and Bertrand Competition Yield Cournot Outcomes.” The Bell Journal of Economics 14(1983):326–37.Google Scholar
Kusnadi, A., Nikolov, Z.L., and Howard., J.A. “Production of Recombinant Proteins in Transgenic Plants: Practical Considerations.” Biotechnology and Bioengineering 56(1997):473–84.Google Scholar
Marketing Research Bureau. Personal Communication. March 2004.Google Scholar
Millan, F.A., Mingo-Castel, A., Michael, M., and Danieli., H. “A Chloroplast Transgenic Approach to Hyper-express and Purify Human Serum Albumin, a Protein Highly Susceptible to Proteolytic Degradation.” Plant Biotechnology Journal 1(2003):71–79.Google Scholar
Misson, D., and Curling., J. “The Industrial Production Costs of Recombinant Therapeutic Proteins Expressed in Transgenic Corn.” Bio-Pharm 13(2000) :48–54.Google Scholar
Mulesky, M., Oishi, K.K., and Williams, D. “Chloro-plasts Transforming Biopharmaceutical Manufacturing.” Biopharm International (September 2004). Internet site: http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=126235&sk=&date=&pageID=6 (Accessed August 13, 2008).Google Scholar
Nikolov, Z.L., and Woodard., S.L. “Downstream Processing of Recombinant Proteins from Transgenic Feedstock.” Current Opinion in Biotechnology 15(2004):479–86.Google Scholar
Oehmke, J.F., and Wolf, C.A. “Is Monsanto Leaving Money on the Table? Monopoly Pricing and Cotton Value with Heterogenous Adopters.” Journal of Agricultural and Applied Economics 36(2004):705–18.Google Scholar
Qin, C.Z., and Stuart., C. “Bertrand versus Coumot Revisited.” Economic Theory 10(1997):497–507.Google Scholar
Rader, R.A. Biopharma: Biopharmaceutical Products in the US Market, 2nd ed. Rockville, MD: Biotechnology Information Institute, 2003.Google Scholar
Rausser, G., Scotchmer, S., and Simon., L. “Intellectual Property and Market Structure in Agriculture.” Conference on the Shape of the Coming Agricultural Biotechnology Transformation: Strategic Investment and Policy Approaches from an Economic Perspective, Ravello, Italy, June 17–18, 1999.Google Scholar
Renkoski, M.A. “Marketing Strategies for Biotechnology Firms: Implications for U.S. Agriculture.” Journal of Agricultural and Applied Economics 29(1997): 123–28.Google Scholar
Robson, A.J. “Stackelberg and Marshall.” The American Economic Review 80(1990):69—82.Google Scholar
Saloner, G. “Cournot Duopoly with Two Production Periods.” Journal of Economic Theory 42(1987): 183–87.Google Scholar
Shulman, S.R., DiMasi, J.A., and Kaitin., K.I. “The Impact of the Waxman-Hatch Act on New Drags and Biologies Approved 1984—1995.” The Journal ofBiolaw & Business 4(1999):63–68.Google Scholar
Tasnádi, A. “Price vs. Quantity in Oligopoly Games.” International Journal of Industrial Organization 24(2006):541–54.Google Scholar
Teece, D.J., ed. The Competitive Challenge: Strategies for Industrial Innovation and Renewal. Cambridge, MA: Ballinger Publishing Company, 1987.Google Scholar
The New York Times. “Cutting Dosage of Expensive Drugs Spurs a Debate.” March 16, 2008.Google Scholar
Van Damme, E., and Hurkens., S. “Endogenous Stackelberg Leadership.” Games and Economic Behavior 28(1998): 105–29.Google Scholar
Wall Street Journal. “Why Genzyme Can Charge so Much for Cerezyme?” November 16, 2005.Google Scholar
Watler, P.K. “Processing Design & Economics for Large Scale Monoclonal Antibody Manufacturing.” IBC's 8th conference on Antibody Production and Downstream Processing, San Diego, February 8-12, 2002.Google Scholar
Wilke, D. and Katzek., J.A. “Primary Production of Biopharmaceuticals in Plants—An Economically Attractive Choice?” European Biopharmaceutical Review (Autumn 2003 Issue).Google Scholar
Zimm, A. “Biotech Firms Become more Tempting Targets.” The Philadelphia Inquirer. January 15, 2007. Internet site: http://www.philly.com/mld/inquirer/business/16461995.htm (Accessed April 24, 2007).Google Scholar